Cosmo Pharmaceuticals
(OTC) CMOPF
Cosmo Pharmaceuticals Financials at a Glance
Market Cap
$1.46B
Revenue (TTM)
€371.03M
Net Income (TTM)
€129.63M
EPS (TTM)
-$0.25
P/E Ratio
-354.05
Dividend
$2.46
Beta (Volatility)
0.18 (Low)
Dividend
$2.46
Beta (Volatility)
0.18 (Low)
Price
$90.00
Volume
385
Open
$88.34
Price
$90.00
Volume
385
Open
$88.34
Previous Close
$90.00
Daily Range
$86.16 - $90.00
52-Week Range
$64.37 - $169.90
Estimated Earnings Date
Jul 23, 2026
Dividend
$2.46
Beta (Volatility)
0.18 (Low)
Price
$90.00
Volume
385
Open
$88.34
Previous Close
$90.00
Daily Range
$86.16 - $90.00
52-Week Range
$64.37 - $169.90
Estimated Earnings Date
Jul 23, 2026
CMOPF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cosmo Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
324.5
CEO
Giovanni di Napoli, MBA
Website
www.cosmopharma.comHeadquarters
Dublin, 2, IE
CMOPF Financials
Key Financial Metrics (TTM)
Gross Margin
49%
Operating Margin
-5%
Net Income Margin
-3%
Return on Equity
-75%
Return on Capital
-1%
Return on Assets
-1%
Earnings Yield
-0.28%
Dividend Yield
2.74%
Payout Ratio
-8.99%
Stock Overview
Market Cap
$1.46B
Shares Outstanding
16.19M
Volume
385
Avg. Volume
417.047
Financials (TTM)
Gross Profit
€48.77M
Operating Income
-€10.48M
EBITDA
€2.36M
Operating Cash Flow
-€11.61M
Capital Expenditure
-€4.23M
Free Cash Flow
-€15.84M
Cash & ST Invst.
€122.63M
Total Debt
€4.26M
Cosmo Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
€52.52M
+6.9%
Gross Profit
€24.44M
-14.7%
Gross Margin
46.53%
N/A
Market Cap
$1.46B
N/A
Market Cap/Employee
$4.54M
N/A
Employees
321
N/A
Net Income
-€1.60M
+75.0%
EBITDA
€2.19M
-61.3%
Quarterly Fundamentals
Total Cash
€122.63M
+143.9%
Total Debt
€4.26M
+131.7%
Accounts Receivable
€25.59M
-10.1%
Inventory
€10.42M
-26.6%
Long Term Debt
€3.55M
+277.1%
Short Term Debt
€1.28M
+42.3%
Return on Assets
-0.59%
N/A
Return on Invested Capital
-0.98%
N/A
Free Cash Flow
-€14.26M
-187.8%
Operating Cash Flow
-€12.70M
-170.0%